A 49-year-old previously healthy woman presented with acute painless visual loss in the right eye, a right relative afferent pupillary defect, and a normal fundus examination. She was diagnosed with retrobulbar "optic neuritis" and given a course of intravenous steroids. Despite treatment, however, she continued to lose vision and serial visual field testing confirmed a junctional scotoma in the fellow eye. Cranial magnetic resonance imaging (MRI) showed a mass at the junction between the right optic nerve and the anterior aspect of the chiasm and a right frontal lesion that proved to be multicentric glioblastoma multiforme. Clinicians should be aware of the possibility of aggressive neoplasm in the differential diagnosis of retrobulbar optic neuritis.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5858864 | PMC |
http://dx.doi.org/10.1080/01658107.2017.1350194 | DOI Listing |
An assessment scheme is proposed to evaluate GBM gross tumor core and T2-FLAIR hyper-intensity segmentations on preoperative multicentric MR images as a function of tumor morphology and MRI characteristics. 74 gross tumor core and T2-FLAIR hyper-intensity BraTS-Toolkit and DeepBraTumIA automatic segmentations, and 42 gross tumor core neurosurgeon manual segmentations were accordingly evaluated. Brats-Toolkit and DeepBraTumIA generally provide accurate segmentations, particularly for the most common round-shaped or well-demarked tumors, where: (1) gross tumor segmentation correctly includes necrosis and contrast enhanced tumor in 100% and 97.
View Article and Find Full Text PDFActa Neuropathol Commun
January 2025
Department of Neurosurgery, Baylor College of Medicine, Houston, TX, USA.
Glioblastoma is the deadliest primary brain tumor, largely due to inevitable recurrence of the disease after treatment. While most recurrences are local, patients rarely present with a new discontiguous focus of glioblastoma. Little is currently known about the genetic profile of discontiguous recurrences.
View Article and Find Full Text PDFClin Oncol (R Coll Radiol)
December 2024
Department of Neurosciences, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia.
Background: Isocitrate dehydrogenase [IDH]-wildtype glioblastoma is an aggressive brain cancer associated with high recurrence and poor overall survival.
Aim: Our study aims to explore the prognostic effects of radiotherapy [RT] alone versus concomitant RT with temozolomide [TMZ].
Methods: A multicentre retrospective study included a cohort of 244 patients diagnosed with IDH-wildtype glioblastoma, and it was analysed from 2013 to 2020.
Eur Radiol
November 2024
Department of Radiology, Leeds Teaching Hospitals NHS Trust, England, UK.
Purpose: To assess the effect of different intensity standardisation techniques (ISTs) and ComBat batch sizes on radiomics survival model performance and stability in a heterogenous, multi-centre cohort of patients with glioblastoma (GBM).
Methods: Multi-centre pre-operative MRI acquired between 2014 and 2020 in patients with IDH-wildtype unifocal WHO grade 4 GBM were retrospectively evaluated. WhiteStripe (WS), Nyul histogram matching (HM), and Z-score (ZS) ISTs were applied before radiomic feature (RF) extraction.
BMC Neurol
November 2024
Radiation Oncology Center Mittelland, Kantonsspital Aarau, Aarau, Switzerland.
Background: 90% of glioblastomas (GBM) relapse within two years of diagnosis. In contrast to the initial setting, there is no standard management for recurrent disease and options include hypofractionated stereotactic re-irradiation (re-mHSRT). The aims of this study were to investigate re-mHSRT practice in Swiss neuro-oncology centres.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!